Response to Cardiac Resynchronization Therapy of Previously Right Ventricular Paced Heart Failure Patients
NCT ID: NCT01466621
Last Updated: 2016-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
743 participants
OBSERVATIONAL
2011-10-31
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot Study Comparing the Programmed Delay Between the Atrial and Ventricle Interval
NCT00794183
Application of Right Atrial Left Ventricular Fusion Pacing in Patients With CRT Indications
NCT03071978
Effects of CRT Optimization as Assessed by Cardiac MR
NCT04763460
Response To Cardiac Resynchronization Therapy In Heart Failure: Role Of Arterial Stiffness
NCT00970476
Combining Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in CRT Treatment
NCT01426321
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary hypothesis is that patients upgraded to CRT from a RV pacemaker respond better than those receiving CRT as a first time device. To test this hypothesis the investigators will compare changes in cardiac size and function, and hospitalization and survival rates between the two patient groups.
The second hypothesis will investigate whether changes in septal dyssynchrony are correlated with changes in ejection fraction in previously RV paced patients. The investigators believe that the patients with the most improvement in septal dyssynchrony due to RV pacing will see the greatest improvement in LV function following upgrade to CRT. A significant correlation between change in IM-S and change in EF will support the hypothesis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Previously RV Paced
Patients who were RV paced prior to receiving a cardiac resynchronization therapy device.
No interventions assigned to this group
Non-Previously RV Paced
Patients who received a CRT device without being previously RV paced.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* QRS duration \> 120 msec
* Pre-CRT ejection fraction =\< 35%
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boston Scientific Corporation
INDUSTRY
Allina Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alan J Bank, MD
Role: PRINCIPAL_INVESTIGATOR
United Heart & Vascular Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
United Heart & Vascular Clinic
Saint Paul, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ISRCRM110009(Boston Sci Corp)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.